Brief: Spruce Biosciences Completes Enrollment In Cahmelia-204 Study For Adult Classic Congenital Adrenal Hyperplasia
22/01/2024 13:15
Jan 22 (Reuters) - Spruce Biosciences Inc SPRB.O :
* SPRUCE BIOSCIENCES COMPLETES ENROLLMENT IN CAHMELIA-204
STUDY
FOR ADULT CLASSIC CONGENITAL ADRENAL HYPERPLASIA
* SPRUCE BIOSCIENCES INC - 100 PATIENTS ENROLLED, EXCEEDING
TARGET
ENROLLMENT OF 90 PATIENTS
* SPRUCE BIOSCIENCES INC - TOPLINE RESULTS FOR CAHMELIA-204
ANTICIPATED IN Q3 OF 2024
Source text for Eikon: ID:nBw9HqkfJa
Further company coverage: SPRB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spruce Biosciences
See all newsSpruce Biosciences, Inc. reports results for the quarter ended June 30 - Earnings Summary
Spruce Biosciences Q2 net loss widens on higher expenses
Spruce Biosciences, Inc. expected to post a loss of $5.80 a share - Earnings Preview
Brief: Spruce Biosciences Appoints Adrian Quartel, M.D., Ffpm, As Chief Medical Officer
Brief: Spruce Biosciences Announces Data Presentation At The 18Th International MPS Symposium